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Novel psychoactive substances include synthetic cannabinoids, cathinone 
derivatives, psychedelic phenethylamines, novel stimulants, synthetic 
opioids, tryptamine derivatives, phencyclidine-like dissociatives, 
piperazines, GABA-A/B receptor agonists, a range of prescribed 
medications, psychoactive plants/herbs, and a large series of performance 
and image enhancing drugs. Users are typically attracted by these 
substances due to their intense psychoactive effects and likely lack of 
detection in routine drug screenings. This paper aims at providing 
psychiatrists with updated knowledge of the clinical pharmacology and 
psychopathological consequences of the use of these substances. Indeed, 
these drugs act on a range of neurotransmitter pathways/receptors whose 
imbalance has been associated with psychopathological conditions, 
including dopamine, cannabinoid CB1, GABA-A/B, 5-HT2A, glutamate, and 
k opioid receptors. An overall approach in terms of clinical management is 
briefly discussed as well.  
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In parallel with a decrease/stabilization of the use of internationally 
controlled drugs (1), the market of novel psychoactive substances is on 
the rise year on year. The diffusion of these substances has been 
identified in 94 countries/territories (2), with some 5% of 19-24 years old 
European people having already experimented with them. The web plays 
a major role in shaping this unregulated market (3), with users being 
attracted by these substances due to both their intense psychoactive 
effects and likely lack of detection in routine drug screenings (4).  
Overall, novel psychoactive substances are defined as new 
narcotic/psychotropic drugs which are not controlled by the United 
Nations’ 1961 Narcotic Drugs/1971 Psychotropic Substances Conventions, 
but which may pose a public health threat (5). However, “novel” will not 
necessarily mean here a new development, but will refer to substances 
that have recently become popular/available, constituting a reason of 
current/potential public health concern.  
In particular, there are increasing levels of concern about the onset 
of acute/chronic psychopathological manifestations associated with the 
intake of a range of novel psychoactive substances (3,6,7). Here we 
provide an overview of the clinical pharmacology of the few hundred 
substances available (4,8,9) and the psychopathological disturbances they 
can produce.   
We searched Medline/PubMed for studies using the terms “new 
psychoactive substances”, “novel psychoactive substances”, “legal highs”, 
“designer drugs”, “research chemicals”, “smart drugs”, and “emerging 
drugs of abuse”. A similar search was carried out for the main groups of 
substances and associated psychiatric manifestations. Where no 
information relating to the index substances was available from the peer 
reviewed literature, specific websites were identified by typing the index 
substance keywords on Google, with selection and analysis of fora 
posts/threads.  
 
 
Synthetic cannabimimetics 
  
Synthetic cannabimimetic (SC) preparations are composed by a dried 
plant, marijuana-like, base and a sprayed mixture of SCs. Oral/e-
liquid/injectable SC formulations are also available (10-12). Within any 
given “Spice” package, usually a range of different SC molecules (13) 
and/or further psychoactives (14-20) can be identified. Batches of the 
same brand may possess highly variable SC concentrations (21).  
It is likely that a few hundreds of SC molecules are currently 
available (8,9). SCs possess high/very high cannabinoid receptor binding 
affinity levels, with a significantly higher dose-response efficacy than 
tetrahydrocannabinol itself (22,23). In addition to this, some SCs show 
further pharmacodynamic actions (24) which may per se be a reason of 
clinical concern, such as N-methyl-D-aspartate (NMDA) receptor 
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antagonism (25,30) and/or monoamine oxidase (MAO) inhibitory 
properties (26). Furthermore, almost all SCs possess indole-derived 
structures, which may in itself facilitate 5-HT2A receptor dysfunction, 
typically associated with both hallucinations/psychosis (27-30) and the 
serotonin syndrome (31). Further, the recent trend of SC fluorination may 
increase the compounds’ lipophilicity, hence enhancing the absorption 
through biological membranes/blood brain barrier (32,33).  
The acute SC intoxication is characterized by agitation/anxiety and 
visual/auditory hallucinations (34-36), together with tachycardia, 
hypertension, mydriasis, hyperglycaemia, dyspnoea, vomiting and 
seizures. Further SC-related medical complications may include stroke, 
encephalopathy, myocardial infarction and acute kidney injuries (37-40).  
A number of analytically confirmed accidental deaths/suicides have 
been related to SC ingestion, either on their own or in combination with 
other compounds (41-51). Long-term SC misuse may be associated with 
both tolerance/dependence (35,52) and a severe/prolonged withdrawal 
syndrome (53-56). A risk of developing psychosis in chronic marijuana 
users has repeatedly been described, and a correlation with the dosage 
ingested has been reported (57). Similarly, SC intake has been associated 
with the occurrence of florid/acute transient psychosis, relapse/worsening 
of a pre-existing psychosis, persisting psychotic disorders/”spiceophrenia” 
(6), and manic-like symptoms or relapse of pre-existing bipolar disorder 
(58,59).  
 
 
Synthetic cathinones 
 
Synthetic cathinones have been first detected by our web-mapping 
research group in 2008 (4). They are beta-ketophenethylamines 
structurally similar to amphetamines/catecholamines, with subtle 
variations that alter their chemical properties, potency, pharmacokinetics 
and pharmacodynamics. Their popularity was driven by the lack of 
availability or the poor purity of cocaine or 3,4-methylenedioxy-
methamphetamine (MDMA, “Ecstasy”), combined with little, if any, legal 
restrictions (3). 
Typically, synthetic cathinones are snorted or ingested orally or 
injected. For mephedrone, the half-life is as short as one hour, hence the 
re-dosing risk (60). Each synthetic cathinone has variable effects and 
potency levels on serotonin, dopamine and noradrenaline pathways, but 
all typically possess sympathomimetic/amphetamine-like effects (8,9). 
Cathinone-related psychoactive effects include increased alertness, 
euphoria, excited delirium, hallucinations, agitation and aggression, 
associated with tachycardia, hypertension and dilated pupils. Abdominal 
pain, flushing, sweating, chills, restlessness and anxiety can be observed 
as well (8,9,61). Mood disturbances and paranoid ideation have been 
observed in chronic users (61-64). Additional reported mephedrone 
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serious effects include hyperthermia, rhabdomyolysis, renal failure and 
seizures.  
Fatalities have been associated with mephedrone (47,61,62), 
methylone and butylone (65). A significant proportion of synthetic 
cathinones’ users report tolerance, dependence or withdrawal symptoms 
(66). Abstinent methcathinone users may present with decreased striatal 
dopamine transporter density on positron emission tomography scans, 
suggesting the potential risk for long-term psychiatric problems (67). 
 
 
Novel derivatives of “classical” psychedelic phenethylamines/ 
MDMA-like drugs 
 
MDMA (“Ecstasy”) is only one of the psychedelic phenethylamine 
products. Recent and popular appearances into the drug scenario include 
a few 2C molecules, such as 2,5-dimethoxy-4-bromophenethylamine (2-
CB, “Nexus”) (68), 2,5-dimethoxy-4-iodophenethylamine (2C-I) (69), and 
2,5-dimethoxy-4-ethylphenethylamine (2C-E) (70). Most 2C drugs show 
affinity for 5-HT2A receptors, whilst some of them inhibit the 
dopamine/noradrenaline/serotonin reuptake as well (3). They may be 
purposefully or unintentionally ingested as MDMA substitutes. With 
MDMA-like drugs enhanced mood, increased energy, openness, and 
perceptual alterations are typically reported, together with a range of 
serotonergic and sympathomimetic toxicity effects, including tachycardia, 
hypertension, metabolic acidosis, convulsions, rhabdomyolysis, mydriasis, 
vomiting, diarrhoea and thrombocytopenia; acute renal failure and 
hyperthermia are a reason of particular concern (3,7,71,72).  
3C-bromo-Dragonfly (“B-Fly”) has been described as a powerful/long 
lasting (up to 3 days of psychoactive effects) drug, previously associated 
with long-standing hallucinations, mood elevation, paranoid ideation, 
confusion, anxiety, and flashbacks (73).  
25C-NBOMe (“N-bomb”, “Pandora”; 74) is one of the most popular 
NBOMe compounds, a group of high potency drugs which are currently a 
reason of public health concern (8,9). Sold online as legal lysergic acid 
and typically ingested orally or sublingually, “N-bomb” is a partial agonist 
of 5-HT2A receptors. Its effects include stimulation, hallucinations, 
dissociation, anxiety, aggression and unpredictable violent episodes (74).  
Para-methoxyamphetamine (PMA, “Dr. Death”); 4-
methyltioamphetamine (4-MTA, “flatliners”); 6-(2-aminopropyl) 
benzofuran (6-APB, “Benzofury”); “B-Fly”; and “N-bomb” have all been 
implicated in a number of related acute toxicity events and fatalities 
(47,73,74). 
 
 
Novel stimulants  
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4,4-dimethylaminorex (4,4-DMAR, “Serotoni”) is a derivative of 
aminorex (75,76) which has been associated in 2013/2014 with some 30 
deaths in Europe (77). Similar to amphetamine-type stimulants (71), 
“Serotoni” is a potent dopamine/noradrenaline releaser whilst inhibiting 
the serotonin transporter as well (78). It may be snorted or ingested (79-
81). It produces euphoria, alertness and agitation lasting several hours 
(80). Hyperthermia and cardiorespiratory problems have also been 
described (82).  
Although synthesized some 70 years ago, methiopropamine (MPA, 
“Blow”), a methamphetamine analogue, started to be recently advertised 
online as a “research chemical” (83-85) to be smoked, ingested or 
snorted. Being a selective noradrenaline/dopamine reuptake inhibitor 
(86), it produces euphoria, hallucinations, alertness and sexual arousal. 
This may be associated with loss of appetite, tachycardia, anxiety, 
nausea, headache, dizziness, skin irritation, difficulty urinating and 
hangover effects (87).  
 
 
Synthetic opioids 
  
These compounds share with morphine most of their clinical 
pharmacological effects, including: analgesia, sedation, euphoria and risk 
of respiratory depression.  
AH-7921 (“doxylam”) is equipotent to morphine (88). Although first 
synthesized some 45 years ago, it is now available online in powder form 
to be snorted or ingested. A few related fatalities have recently been 
identified (82).  
Although never marketed as such, MT-45 was developed in the early 
1970s as a potential analogue of the analgesic lefetamine (89). Being a 
mu/delta/sigma opioid receptor agonist (90), it is currently a popular 
compound, either on its own or in combination with synthetic cathinones 
(“Wow”, 82). MT-45 intake has been associated with respiratory 
depression, loss of consciousness and ototoxicity (91) and a number of 
fatalities as well (82).      
Further popular drugs include nortilidine, which is an NMDA receptor 
antagonist and dopamine reuptake inhibitor equipotent to morphine (92); 
the high potency mu-opioid agonists W15 and W18 (93); 4-fluoro-butyr-
fentanyl (“4FBF”) and IC-26 (“methiodone”), a methadone analogue.   
 
 
Synthetic cocaine substitutes 
 
RTI-111 is a potent stimulant acting as an inhibitor of serotonin, 
dopamine and noradrenaline reuptake (94). RTI-121, developed in the 
1990s, is a potent/long-lasting stimulant acting as selective dopamine 
reuptake inhibitor (95). Lastly, RTI-126 (96) may present with a potency 
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5-fold higher than cocaine (97). When snorted, these compounds are 
associated with alertness, euphoria, talkativeness, insomnia and 
prolonged residual tension/anxiety (87).  
 
Novel tryptamine derivatives 
 
Synthetic tryptamines appeared on illicit drug markets throughout 
the 1990s (98), to be replaced over the last few years by cathinones, 
phenethylalamines and piperazines (82,99).  
Nevertheless, novel tryptamines (e.g., N-diallyl-5-methoxy-
tryptamine, 5-MeO-DALT; alpha-methyltryptamine, AMT; 5-methoxy-
alpha-methyltryptamine, 5-MeO-AMT; N,N-diallyl-4-hydroxytryptamine, 
4-HO-DALT; 5-methoxy-diisopropyl-tryptamine, 5-MeO-DIPT; 5-methoxy-
N,N-dimethyltryptamine, 5-MeO-DMT; N,N-diethyltryptamine, DET; 5-(2-
aminopropyl)indole, 5-IT) continue to appear on the online drug scenario 
(2,82,100,101).  
Most exogenous tryptamines are psychoactive hallucinogens found 
naturally (102-106), notably in Delosperma species plants (DMT, 5-MeO-
DMT), hallucinogenic fungi (psilocin, 4-OH-DMT), and amphibians 
(bufotenin). Endogenous bufotenin and dimethyltryptamine (DMT) have 
been detected in humans as well (107-109), even though their biological 
functions remain unclear.  
The predominant clinical effects of tryptamines, associated with both 
agonist activities at 5-HT2A receptors and serotonin transporter inhibition 
(110-117), consist in visual hallucinations, alterations in sensory 
perception, distortion of body image, depersonalization, marked mood 
lability and anxiety/panic (98,118). Untoward effects include agitation, 
tachyarrhythmia and hyperpyrexia (111). There are small numbers of 
confirmed post-mortem toxicology reports on tryptamines, mainly relating 
to AMT (47).   
Bufotenin (119) is found on the skin of various species of the toad 
Bufo genus, in Amanita mushrooms, and in Anadenanthera peregrina/ 
Piptoderma peregrina plants (120). Its psychoactive effects are mainly 
due to its enzymatic conversion to 5-MeO-DMT. Typically, consumers 
smoke the crystals obtained by drying the liquid taken from the frogs, but 
both oral and intravenous use have been recently reported as well.  
AMT is available mainly from the web, in tablet and liquid 
formulations. Visual illusions and euphoria have been reported (121). 5-
MeO-AMT and 5-MeO-DMT own a structure similar to amphetamine, 
hence explaining their sympathomimetic effects (98,99). 5-IT, a positional 
AMT isomer and a substituted phenethylamine, has been made available 
since 2012. It possesses both hallucinogenic and stimulant effects 
(98,99). 
 
 
GABA-A/B receptor agonists 
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Currently used in some countries to treat narcolepsy and alcohol 
withdrawal (122), gamma-hydroxybutyric acid (GHB, “liquid Ecstasy”) 
was developed as an anaesthetic some 50 years ago. It can be produced 
in clandestine laboratories using a relatively simple synthesis with readily 
available and inexpensive source materials. It is typically ingested orally. 
Gamma-butyrolactone (GBL) and 1,4-butanediol, both industrial 
chemicals, are also currently used for their GHB-like effects, with GBL 
being a high lipophilicity/high potency GHB pro-drug.  
GHB intake is associated with both increased central dopamine levels 
and activation of GABA-A/B receptors (123). GHB elimination half-life is 
27 minutes, hence the re-dosing risk (124). Euphoria and calmness are 
initially observed after ingestion. A low/moderate oral dose of 10 mg/kg 
(0.75 g) can produce short-term amnesia, hypotonia, lowering of 
inhibitions and libido increase. Higher dosages lead to drowsiness, 
nausea, vomiting, muscle stiffness, dizziness, confusion, delirium, 
hallucinations, convulsions and cardiopulmonary depression.  
GHB is highly addictive (125), with its withdrawal syndrome being 
characterized by insomnia, muscular cramping, tremor and anxiety (126). 
Initial UK data indicate that there have been 159 GHB/GBL-associated 
fatalities reported over the last decade. Most deaths (79%) were 
accidental and GHB/GBL alone was implicated in 37% of cases (127). 
Baclofen is a GABA-B agonist (128) showing both anxiolytic and 
analgesic properties whilst exerting some beneficial alcohol, cocaine and 
nicotine anti-craving effects (129-132). It can also be used for both 
GHB/GBL and phenibut withdrawal/detoxification (133). Most typically, 
misusers present with a history of substance abuse/self-medication with 
other substances and start taking large dosages after being regularly 
prescribed with baclofen for medical reasons (134).  
Although signs of toxicity may be identified with as little as 100 mg 
of baclofen (135), misusers report the intake of higher dosages in order 
to achieve the desired effects, including euphoria, relaxation and anxiety 
obliterating/antidepressant-like effects, similar to those reported after   
phenibut, GHB and pregabalin intake (80,136).  
Several deaths after baclofen overdose have occurred (137). The 
acute intoxication is characterized by severe hypotonia, delirium, 
sedation, respiratory depression, cardiac conduction abnormalities, and 
possibly coma. Baclofen should always be withdrawn gradually (138).  
Common presenting withdrawal features are muscular hyperactivity, 
hyperthermia, metabolic derangements, rhabdomyolysis, convulsions and 
delirium, with issues similar to the serotonin syndrome (139).  
Phenibut (“PB”) is being used in Russia and Latvia for the treatment 
of anxiety/alcohol withdrawal symptoms and as a nootropic (140). As a 
dietary supplement, it is freely available online. When misused, PB is 
typically taken orally in dosages (e.g., 1-3 g) notably superior to the 
therapeutic ones, thus leading to a risk for overdose. At these dosages, 
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PB acts as agonist at GABA-A/B receptors, whilst stimulating 
dopamine/serotonin neurotransmission as well (141,142).  
Its use may rapidly lead to dependence/tolerance (143), with related 
withdrawal symptoms being managed with baclofen (144). Withdrawal 
signs/symptoms may include visual and auditory hallucinations, 
psychomotor agitation, derealization, depersonalization, increased light 
and sound sensitivity, muscle pain/twitches, tachycardia, nausea, tremor 
and insomnia (145). Acute intoxication is characterized by tachycardia, 
visual hallucinations, tremor, nausea and vomiting, with the possible 
occurrence of the serotonin syndrome (146,147).  
 
 
Phencyclidine-like dissociative drugs 
 
Dissociative drugs are both popular and a cause of clinical concern 
(148-150). Ketamine hydrochloride (“special K”) is of widespread use 
worldwide.  
Ketamine is usually diverted from the veterinary clinics, where it is 
used for surgical interventions. Its hallucinogenic effects are related to 
central 5-HT2A agonism (151), NMDA receptor antagonism (152), and 
high affinity for mu/delta/sigma opioid receptors (153).  
When misused, ketamine can be injected or snorted or smoked or 
administered rectally, in a dosage range of 25-300 mg. Its psychotropic 
effects include referential thinking, dissociation, depersonalization, 
psychotic experiences and out-of-body/near death experiences (e.g., the 
“K-hole”, 150). In the long term, tolerance, dependence, withdrawal signs 
and flashbacks are described, with schizotypal symptoms and perceptual 
distortions possibly persisting after cessation (154).  
Approximately one third of patients with long-term recreational 
ketamine use present with both urological (“k bladder”, e.g., dysuria, 
suprapubic pain, haematuria, decreased bladder capacitance, abnormal 
bladder histology, hydronephrosis) (155) and intestinal (“k cramps”) 
(153) problems. High dosage self-administration may be associated with 
both cardiovascular and respiratory toxicity. Numbness, muscle weakness 
and impaired perception can result in falls, trauma or burns. Risks have 
also included drowning, death from hypothermia due to lying outside in 
winter, traffic accidents and becoming a crime victim (47,150).   
Methoxetamine (MXE, “Special M”) has recently entered the market 
as a structural analogue of ketamine in order to elude the legislative 
sanctions (149). MXE may be swallowed or insufflated or injected or used 
rectally or sublingually at a dosage range of 5-100 mg (9,80,87,136).  
MXE possesses NMDA receptor antagonism, dopamine releasing and 
serotonin transporter inhibiting activities (153). Most users report long-
lasting dissociative effects (e.g., the “M-hole”, 156). Although having 
been marketed as “bladder friendly”, initial preclinical studies are a 
reason of clear concern (157), with cerebellar features and seizures being 
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unique to “special M” intoxications (158). A number of methoxetamine 
analytically confirmed fatalities have been described (148). 
Diphenidine (DND) and methoxphenidine (MXP) are novel lefetamine 
derivatives acting as NMDA receptor antagonists (159), serotonin 
transporter inhibitors, dopamine agonists, and opioid agonists (87). They 
can be ingested or insufflated or injected at a dosage range of 50-150 
mg, with a duration of effects of 8-12 hours (87). Interestingly, a range of 
serotonin syndrome signs/symptoms have been associated with DND/MXP 
high dosage ingestion (80,87,136).  
Dextromethorphan (DXM) is an over-the-counter antitussive lacking 
of strong mu-opioid agonist properties but acting as an NMDA receptor 
antagonist (159) whilst possessing serotonin transporter inhibiting 
activities (160). With long-term DXM abuse, psychotic disturbances can 
be observed (8,9). Abrupt DXM cessation has been associated with 
withdrawal symptoms (e.g., vomiting, diarrhoea, myalgias, restlessness, 
night sweats, insomnia, anxiety, but also hallucinations and flashbacks) 
(161). DXM high dosage ingestion may be associated with occurrence of 
the serotonin syndrome (160). 
 
 
Piperazines 
 
Benzylpiperazine (BZP) was initially trialled as an antidepressant 
some 40 years ago, but never entered the market. Especially in the past, 
it was included in “fake” Ecstasy tablets. It is an 5-HT2A receptor agonist, 
which explains its hallucinogenic effects at higher doses.  
Piperazines have become popular to mimic Ecstasy effects, with the 
recently introduced “Molly” being typically an MDMA/piperazine 
combination (162). Their effects are similar to those of amphetamine, but 
less intense (8,9,162). Their ingestion is typically associated with 
stimulant effects, but at higher dosages hallucinations can be reported as 
well. Seizures can occur in as many as 1 in 5 patients presenting with 
piperazine toxicity, with hyponatremia, serotonin syndrome and renal 
failure having been described as well (162).  
Meta-chlorophenylpiperazine (mCPP) is the main trazodone/ 
nefazodone metabolite. Its high dosage ingestion can produce euphoria, 
hypertension and tachycardia.  
 
 
Herbs/plants  
 
Salvia divinorum (“Sally-D”) has a long history as a divinatory 
psychedelic. Its current use includes smoking or chewing the dried leaves 
containing salvinorin A and B, both k-opioid receptor agonists (163). At 
high dosages, time distortion, vivid imagery, and empathogenic effects 
have been anecdotally reported (80,87,136). When smoked, its clinical 
effects occur within 20-60 seconds and last 5-15 minutes. Its intake may 
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be associated with perceptual disturbances, psychosis, headache, 
irritability and anxiety (80,87,136). Dependence and tolerance have not 
been reported.  
Sceletium tortuosum (“Kanna”) is a traditional Southern Africa 
entheogen (164) currently available as extract, dried-powdered herb, 
tincture, tea bags and seeds. It may be snorted, smoked, chewed or 
swallowed (80,87,136). Desired effects include euphoria, reduction of 
tension, libido enhancement and appetite suppression. The mood-
elevating action is due to the serotoninergic activity of its alkaloids (165), 
e.g. mesembrine, mesembrenone, mesembrenol and tortuosamine. 
Common side effects reported are hypertension, headache and nausea, 
associated with anxiety, irritability and insomnia. A serotonin syndrome 
can occur if it is associated with selective serotonin reuptake inhibitors 
(SSRIs) or MAO inhibitors (MAOIs) (80,87,136).   
Mytragina speciosa (“Kratom”) is a tree native to some Asian 
countries whose leaves contain mitragynine, mitraphylline, 7-
hydroxymitragynine and O-desmethyltramadol. Mytragynine (“biak-biak”) 
is a partial agonist of the mu/delta opioid receptors. 7-hydroxymitraginine 
is a mu-opioid agonist 30-fold more potent than mitragynine. 
Mitraphylline acts both on mu/delta opiate receptors and as an NMDA 
receptor antagonist (119). Kratom may be smoked or brewed or ingested 
as an extract. Users report either an opiate-like sedation, particularly at 
higher dosages, or a cocaine-like stimulation at lower dosages 
(80,87,136). Other clinical effects include severe nausea and vomiting 
associated with visual disturbances. Regular use may lead to dependence 
and opioid-like withdrawal symptoms upon discontinuation. A few related 
fatalities have been reported (47).  
Piper methysticum (“Kava Kava”) is a social/ceremonial drink in 
many South Pacific Islands, with kavalactones and kavapyrones being its 
active constituents (8,9,119). Out of these, desmethoxy-yangonin is a 
reversible MAOI-B, able to increase as well dopamine levels in the nucleus 
accumbens (166). Kavain is a N-terminal acetyltransferase (NAT) 
inhibitor, supposedly with SSRI and NMDA receptor activation properties 
(167). Yangonin acts as a cannabinoid CB1 agonist (168). Kava roots are 
also available in liquid form, tinctures, extracts and tablets. Kava confers 
a rapid onset, long-term sedation (119), but there are several reports of 
associated liver damage or failure (169). 
Ayahuasca is a psychedelic South American brew, traditionally made 
from Banisteriopsis caapi vine (containing the beta-carboline harmala 
alkaloids, possessing reversible MAOI-A properties) and Psychotria viridis, 
a DMT-containing plant (8,9,119). Being metabolized by the digestive 
MAO, DMT is practically inactive if taken orally, unless combined with a 
MAOI. Effects may last 2-6 hours, and include intense visual 
hallucinations, euphoria, paranoid ideation and entheogenic sensations, 
associated with vomiting and/or diarrhoea (8,9,119). 
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Ibogaine is a hallucinogenic alkaloid extracted from the root bark of 
the Western African shrub Tabernanthe iboga, traditionally used as a 
sacrament (8,9,119). It is an 5-HT2A agonist, dopamine agonist, NMDA 
receptor antagonist and k-opioid receptor agonist (170). Its ingestion is 
associated with visual hallucinations and entheogenic effects, possibly 
associated with ataxia, nausea, vomiting and arrhythmias (171).  
A recent increase in online discussions relating to the possible misuse 
of magnolols has been identified by our research group (172). The bark 
extract of Magnolia officinalis is typically used in the traditional oriental 
medicine for the treatment of insomnia, anxiety and allergies (173). 
Honokiol and magnolol, the main constituents of its extracts, are both 
weak cannabinoid CB2 and GABA-A receptor agonists (174). Magnolol is 
then metabolized into its 20-fold more potent metabolite 
tetrahydromagnolol, active at cannabinoid CB1/CB2 receptors (174).  
Cannabis- and benzodiazepine-like effects (e.g. sedation, reduced 
attention and concentration, headache) are being reported (80,87,172).  
Hydrangea paniculata/Hortensia is a common ornamental plant. Its 
misuse may be associated with a range of cannabis-like effects, e.g. 
euphoria, sedation, confusion, dizziness and headache (80,87,136). It 
may be smoked, or ingested in capsules, extracts, teas or sugar syrup.   
Datura stramonium is another common plant well known for its 
mind-altering properties associated with anti-cholinergic 
peripheral/central effects (e.g.: hallucinations, delusions, bizarre 
behavior, and euphoria) associated with xerostomia, severe 
mydriasis/photophobia, confusion, disorientation, tachycardia, and 
amnesia (8,9,80,87,119).   Related fatal medullary paralysis, arrhythmias 
and cardiovascular collapse events have been reported (47).  
Nauclea latifolia is a flowering, tramadol-containing, sub-Saharan 
plant (175), used recreationally in alternative to the prescribed 
medication itself to obtain pain relief, sedation and anxiolytic effects 
(80,87).      
  
 
Prescribed products  
 
Pregabalin is approved in Europe for the treatment of epilepsy/partial 
seizures, neuropathic pain and generalized anxiety disorder. The molecule 
is however also often prescribed off-label for a range of psychiatric 
conditions, including bipolar disorder, alcohol/narcotic withdrawal states, 
and attention-deficit/hyperactivity disorder. In parallel with increasing 
prescribing levels, a growing black market is currently being observed (8, 
9,176,177).  
Potent binding of pregabalin and gabapentin at the calcium channel 
results in a reduction in the release of excitatory molecules. Furthermore, 
they are thought to possess GABA-mimetic properties and direct/indirect 
effects on the dopaminergic “reward” system (177). Overall, pregabalin is 
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characterized by higher potency, quicker absorption rates and greater 
bioavailability than gabapentin (176). 
Typical misusers of these compounds are individuals with a history of 
recreational polydrug use. A range of experiences may be associated with 
gabapentin abuse, including euphoria, improved sociability, opiate-like 
sedation and psychedelic effects (176). Similarly, pregabalin is considered 
an “ideal psychotropic drug” to achieve specific mindsets, including 
sedative effects mixed with euphoria and dissociation.   
Misuse of pregabalin, at dosages up to 3-20 times higher than the 
maximal dosage indicated (176), mostly seems to occur orally, but 
intravenous use, rectal “plugging” and smoking have been reported as 
well. A few drugs are reportedly misused in combination with pregabalin 
or gabapentin, including cannabis, alcohol, lysergic acid, amphetamine 
and GHB (176,177).   
Phenazepam (“Zinnie”) is an old benzodiazepine, currently prescribed 
in the Russian Federation for the treatment of a range of neurological 
disorders as well as for alcohol withdrawal/anxiety, and as a surgery 
premedication (178). Easily accessible online at low prices, it is 
considered five times more powerful than diazepam (179). It can be 
ingested, snorted or injected, either on its own or in combination with 
other substances, with euphoric effects having been described (8,9). 
Reported side effects include amnesia, dizziness, loss of coordination, 
drowsiness, blurred vision, slurred speech and ataxia. Deaths by 
respiratory arrest due to its misuse in combination with other sedatives 
have been reported (180).    
Olanzapine is being anecdotally advised online as the “ideal trip 
terminator” after a psychedelic drug binge (181). Different from current 
medical guidelines, however, the molecule is being self-prescribed, and 
for a few days only, at daily dosages up to 50 mg/die.  
Quetiapine (“Q ball”) is similarly anecdotally considered to “come off 
the psychedelic trip” (181), with typical misusers being clients with a 
previous substance abuse history. Vulnerable subjects (e.g., adolescents, 
inmates) may be particularly at risk (182). Reasons for abuse of atypical 
antipsychotics may include the desire of “feeling mellow” (183).   
There are anecdotal reports of misuse of venlafaxine, particularly in 
combination with other substances (80,87,136), possibly related to the 
increase it produces in dopamine neurotransmission (184,185), 
particularly at the level of the prefrontal cortex (186).  
Recent concerns relating to orphenadrine (an anticholinergic drug) 
misuse have been reported (187). Similarly, misuse of tropicamide (an 
ophthalmic anticholinergic compound producing short-acting mydriasis 
and cycloplegia) has been recently described (188). When misused, 
tropicamide is typically injected intravenously, often in combination with 
other psychoactives. Tropicamide-related psychoactive effects include 
hallucinations, “open eye dreams” and dysphoria, associated with slurred 
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speech, persistent mydriasis, hyperthermia, tremor, convulsions, 
psychomotor agitation, tachycardia and suicidal ideation (188). 
 
 
Performance and image enhancing drugs 
 
Increasing consumption levels of substances known as performance 
and image enhancing drugs (PIEDs) have been recorded (8,9,189). PIEDs 
are drugs, nutrients, drinks, vegetable extracts or potions from a range of 
different sources. 
Among image enhancers, there are increasing levels of concern 
regarding the misuse of the slimming aid dinitrophenol (DNP), whose 
intake has been implicated in a number of UK fatalities (47,190). DNP 
may present with addictive liability levels and its ingestion may be  
associated with euphoria, energy increase, nausea and headache (8,9). 
DNP is proposed online as a metabolism booster to bodybuilders and 
dieters.  
Typically identified in dietary supplements, 1,3-dimethylamylamine 
(DMAA) intake is associated with euphoria and mild stimulant effects, 
together with hypertension, headache, nausea, and vomiting (80,87,111). 
In parallel with concerns about DMAA’s health risks, including deaths 
(191), new synthetic stimulants, including beta-methyl-phenylethylamine 
(BMPEA), N,alpha-diethylphenylethylamine (DEPEA) and more recently 
1,3-dimethylbutylamine (DMBA) have been proposed to online customers 
looking for alternative “natural” dietary supplements. With DMBA, effects 
such as restlessness, mood-enhancement, increased focus, nausea, 
flushing and tachycardia have been reported (80,87,192).  
Melanotan synthetic tanning agents are largely available online, 
aiming at promoting melanogenesis and hair-skin pigmentation. 
Melanotan user groups include aesthetically driven women, body 
dysmorphics and male bodybuilders. Sexual arousal, flushing, nausea, 
weight loss and immune response alterations have been reported 
(193,194). 
A range of natural products, such as those containing Tribulus 
terrestris, are available online. They are particularly popular because of 
their alleged powerful pro-testosterone, muscular strength enhancer, 
natural formula. Both increased sexual arousal (80,87) and psychotic 
episodes (associated with long-term ingestion; 189) have been described.  
Among cognitive enhancers, piracetam, aniracetam and 
centrophenoxine have recently been reported to be abused by healthy 
individuals with the hope to enhance their functions in study and work-
related performances (195). Piracetam is a GABA derivative, originally 
marketed in 1971 as a nootropic (196), due to restored 
neurotransmission and increased brain oxygen consumption (197). With 
high dosage cognitive enhancers’ ingestion, hallucinations and mood 
alterations have been reported (80,136,196). 
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“Natural” sexual performance enhancers are advertised online as 
“safer” alternatives to pharmaceutical phosphodiesterase type 5 
inhibitors. Most popular compounds include yohimbine, Maca, Epimedium 
and Ginkgo Biloba. Their ingestion has been associated with anxiety, 
irritability, hypomanic reactions and inappropriate behaviour 
(80,87,136,198). 
 
 
Discussion 
 
The ever-increasing number of novel psychoactive substances 
emerging worldwide (2,8,9,101) and the parallel changes in drug 
scenarios represent a challenge for psychiatry. In fact, the intake of these 
substances is typically associated with the imbalance of a range of 
neurotransmitter pathways/receptors, and consequently with the risk of 
psychopathological disturbances.  
The occurrence of psychosis has been related to: a) increased central 
dopamine levels (199), associated with the intake of most of these 
substances, including novel psychedelic phenethylamines, synthetic 
cathinones and 4,4-DMAR; b) cannabinoid CB1 receptor activation (200), 
achieved with synthetic cannabimimetics; c) 5-HT2A receptor activation 
(201), reported with NBOMe compounds, latest tryptamine derivatives, 
lefetamine derivatives, DXM and hallucinogenic plants; d) antagonist 
activities at both the NMDA and mGlu2/3 receptors (202), described with  
phencyclidine-like dissociatives; and e) k-opioid receptors’ activation 
(203), typically associated with Salvia divinorum intake.   
Vulnerable subjects, including both children/adolescents and 
psychiatric patients, may be exposed to a plethora of “pro drug” web 
pages, which provide direct drug purchase opportunities and/or drug 
information (e.g., description of the drug effects, dose, chemistry and 
intake experiences). Advanced levels of knowledge related to novel 
psychoactive substances are typically provided by drug fora/blog 
communities’ members (e.g., the “e-psychonauts”, 4).  
It is arguably inappropriate to trust information obtained online 
without independent verification, and only large scale, adequately 
controlled clinical studies can give a clear indication of drug characteristics 
and adverse effects. However, previous studies from our group (4,176) 
have clearly suggested that an increase in online trafficking/debate about 
a specific psychoactive drug typically precedes the occurrence of clinical 
incidents at the population level.  
Consumers of novel psychoactive substances may self-refer 
overnight to accident and emergency departments, when concerned with 
acute medical or psychiatric problems, without disclosing their substance 
intake and showing negative results at the standard drug tests (8,9). It is 
clearly difficult to draw a detailed and universal management plan to cope 
with the behavioural and psychopathological disturbances related to the 
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intake of the virtually few hundreds of substances currently available 
(8,9,162).  
Given the complex or unknown pharmacology of the substances 
possibly ingested by the client, benzodiazepines may be agents of choice 
(3). They may, however, need frequent re-dosing/high dosages to 
achieve adequate sedative effect, and this may be a problem if clients 
have co-ingested alcohol as well (3). Where patients cannot be controlled 
with benzodiazepines alone, propofol and/or antipsychotics may be 
considered (8,9,162), although this may further contribute to the acute 
toxicity effects of the abused substances.  
Treatment of hyperthermia needs to be aggressively planned, and 
this typically involves cooling measures and intravenous fluid 
administration for rhabdomyolysis concern (3). Serotonin syndrome is 
managed using benzodiazepines and cyproheptadine (204). Inpatient 
admission, possibly to intensive care units, may at times be needed 
(8,9,162).  
The increasing levels of misuse of a range of medicinal products, 
otherwise representing a valuable asset in the pharmacological repertoire 
of psychiatry/addiction medicine (177), are a reason of further concern. 
Possible sources of this acquisition may either be diversion of regularly 
prescribed medicines or online/”rogue” pharmacies (205).  
Psychiatrists/physicians who consider prescribing a psychoactive 
molecule possessing a potential for misuse (e.g., pregabalin or 
gabapentin for neurological/psychiatric disorders) should carefully 
evaluate a possible previous history of drug abuse. Furthermore, they 
should be able to promptly identify signs of misuse, and provide 
assistance in tapering off the index medication (177).  
The online market of novel psychoactive substances is unfortunately 
developing far more rapidly than academic research (4). We believe that 
mental health professionals need to be aware of the psychopathological 
effects of these substances. We hope that the present paper may 
represent a useful contribution in this respect.  
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